The positive market research results for Eroxon®, released this morning, provides further support for the company’s ongoing partnering efforts. We continue to believe that MED2002 is a differentiated product with significant potential in both prescription and OTC markets, and look forward to further PK data followed by Phase III start in H1 2018.
16 Oct 2017
N+1 Singer - Futura Medical - Market research supports the commercial potential of Eroxon®
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
N+1 Singer - Futura Medical - Market research supports the commercial potential of Eroxon®
Futura Medical plc (FUM:LON) | 39.1 0.2 1.5% | Mkt Cap: 117.9m
- Published:
16 Oct 2017 -
Author:
Dr Jens Lindqvist -
Pages:
3
The positive market research results for Eroxon®, released this morning, provides further support for the company’s ongoing partnering efforts. We continue to believe that MED2002 is a differentiated product with significant potential in both prescription and OTC markets, and look forward to further PK data followed by Phase III start in H1 2018.